ArticleAmerican journal of cancer research2026
Association between DPAGT1 and Siglec-15 expression and the malignant phenotype of hepatocellular carcinoma.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N-acetylglucosamine phosphotransferase 1 (DPAGT1), a key enzyme involved in protein glycosylation, has been implicated in tumor progression; however, its relationship with sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) in hepatocellular carcinoma (HCC) remains unclear. This study investigated the association between DPAGT1 expression, Siglec-15 expression, and malignant phenotypes in HCC. Bioinformatic analysis of the GEPIA database revealed higher expression of DPAGT1 and Siglec-15 in HCC tissues. Higher DPAGT1 expression was associated with poorer overall survival, whereas Siglec-15 expression showed no significant association with survival outcomes. Although DPAGT1 and Siglec-15 expression levels showed a statistically significant correlation, the correlation strength was weak. Functional experiments demonstrated that DPAGT1 overexpression promoted proliferation, migration, and invasion of HCC cells, whereas DPAGT1 knockdown resulted in reduced malignant phenotypes. Re-expression of Siglec-15 partially alleviated the inhibitory effects associated with DPAGT1 depletion. Similar alterations were observed in Hep-3B cells and a xenograft model, where DPAGT1 modulation was associated with changes in tumor growth, Siglec-15 expression, TGF-β1 levels, AKT phosphorylation, and EMT-related molecular markers. Collectively, these findings suggest that DPAGT1 may contribute to HCC progression and is functionally associated with Siglec-15 expression and EMT-related molecular alterations. Further studies are required to clarify the underlying molecular relationship between DPAGT1 and Siglec-15.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.